brand logo

Should young children be vaccinated against Covid-19?

28 Oct 2021

  • By Max Kozlov
Paediatricians and families in the US are eagerly waiting to see whether the Food and Drug Administration (FDA) will authorise a Covid-19 vaccine for the nation’s roughly 28 million five-11-year-olds. On Tuesday (26), an FDA advisory committee reviewed data from a clinical trial testing a low-dose version of the vaccine made by Pfizer and BioNTech on children in that age group – and voted nearly unanimously to recommend that the FDA grant the shot emergency approval. Anticipating that the FDA and the US Centres for Disease Control and Prevention (CDC) will soon give the vaccine the thumbs up, and that distribution to children will begin in the coming weeks, infectious-disease researchers are now looking ahead to how immunising five-11-year-olds – the largest group of people in the US not yet eligible for the vaccine – will change the course of the pandemic. “It will save lives in that age group,” said Australian Institute of Tropical Health and Medicine in Townsville infectious-diseases modeller Emma McBryde. But it could also have a broader impact, given that many US children aged five-11 have returned to school unvaccinated in the past few months, and the group now accounts for a significant portion of new Covid-19 cases, capable of transmitting the coronavirus SARS-CoV-2 to others.  “For every child’s life you save, you may well save many, many more adult lives,” she said. The benefits outweigh the risks The FDA advisory panel voted in favour of approval on Tuesday, on the basis of clinical-trial data showing that the Pfizer-BioNTech vaccine is about 91% effective at preventing symptomatic SARS-CoV-2 infection in five-11-year olds. Around 4,650 children participated in the trial; nearly two-thirds received vaccine doses that were one-third that of an adult jab (the others received a placebo). In a procedure similar to that used to vaccinate adults with the messenger RNA jab in the US, kids received two doses, three weeks apart. For the children tested, the data show that the vaccine is safe. mRNA-based vaccines have been linked to a very small risk of myocarditis, an inflammation of the heart muscle, and pericarditis, an inflammation of the lining around the heart, particularly in young men. But there were no reports of either condition in the five-11-year olds involved in the trial, which is a very encouraging sign, said University of Utah Health paediatric infectious diseases division chief Andrew Pavia. If the shot were distributed to a larger population, however, regulators would need to watch for any sign of the side effects, Pavia noted. Before the advisory panel’s meeting, an independent FDA review of Pfizer’s data evaluated six fictional US scenarios, with varying levels of virus in the community, and found that, for the most part, the benefits of the vaccine “clearly outweigh the risks”. Officials determined that even if virus levels were very low across the country, the overall benefits of the vaccine would probably still outweigh the potential risks of heart problems, because these conditions typically resolve in a few days after vaccination, unlike Covid-19, which can cause death. Although SARS-CoV-2 is not nearly as lethal in younger people as in older ones – around 440 children aged 5 to 18 have died of Covid-19 in the US, compared with around 724,000 in all age groups, according to the CDC – the combination of kids returning to classrooms and a surge caused by the highly transmissible SARS-CoV-2 Delta variant resulted in a sharp rise in paediatric cases beginning in late July. Of the 6.3 million US children who have tested positive for Covid-19 since the pandemic began, nearly one-third were diagnosed in the 11 weeks up to 21 October, according to an American Academy of Pediatrics report. “To me, the impact of Delta on children in this age group makes the risk side of the equation very compelling,” Pavia said “I don’t think it’ll be a very difficult decision to approve the vaccine.” Looking ahead Covid-19 infections in the US have been dropping since September, after the Delta surge. Most modellers expect that trend to continue until early 2022, regardless of whether the Pfizer vaccine is authorized for five-11-year-olds. That is, unless another variant of concern emerges, said Pennsylvania State University in University Park applied theoretical ecologist Katriona Shea. “If there’s a new variant, that’s like a slap to the system.” Shea co-leads the Covid-19 Scenario Modeling Hub, which in September released its ninth forecast of the pandemic’s trajectory, factoring in how a vaccine for children aged five-11 could affect new US infections and deaths. The forecast, which averages the predictions of nine other modelling teams, shows that although vaccines for kids would lead to lower case counts. “It might not make a huge difference at the population level if we are lucky enough just to stick with the Delta variant”, Shea said. But the data show that if a concerning variant were to emerge by mid-November, inoculating children could make a significant difference to the course of the pandemic in the US. In preparation for US regulators’ possible authorisation of the jabs, the White House last week released a plan to distribute the lower-dose shots to paediatrician’s offices, hospitals and pharmacies. But even if the Pfizer–BioNTech shot is authorised, it remains to be seen how kids in the five-11 age group will feel about getting vaccinated – and whether their caregivers will allow them to. University of Oxford, UK child and adolescent psychiatrist Mina Fazel and her colleagues surveyed nearly 28,000 pupils aged nine-18 at 180 UK schools and found that the younger children were more undecided than their older counterparts. The survey also suggested that social media plays a part: pupils who spent more than four hours a day on social platforms were less willing to receive the vaccine than were those who spent less time on social media. “We have a generation of young people before us who are engaging with information and learning at an unparalleled scale,” Fazel said, adding that it is more important than ever to tailor public-health campaigns for kids. Global implications What the authorisation of a vaccine for US children aged five-11 might mean globally also remains to be seen. Almost 70 countries have fully vaccinated less than one-fifth of their populations and will probably not vaccinate younger children for months, or even years, to come. But some countries, including Israel, are waiting to see the US regulators’ decision before approving their own jabs. Other countries, however, are already vaccinating children under age 12. For instance, Chile, China, Cuba, and the UAE have begun inoculating kids with various Covid-19 vaccines in the past three months. In places where the population has a very low natural immunity to the virus because community transmission has remained low throughout the pandemic, McBryde said, childhood vaccination will be essential. Australia, for example, plans to reopen its international border in November, allowing citizens and permanent residents to leave and enter the country if the vaccination rate in their state of residence has hit 80%. The move will “invite the virus” into the country, McBryde said, so it will be essential to “soften the landing” as much as possible by building up people’s immunity to the virus through vaccination – and that includes children. Shots for children under 12 have not yet been submitted to Australia's regulators for approval. On 25 October, vaccine maker Moderna, based in Cambridge, Massachusetts, said that a low dose of its mRNA-based jab for children aged six-11 is safe and effective, but it has not yet applied for FDA authorisation. Data on Pfizer’s jab for children younger than five is expected by the end of the year, according to a statement the company’s chief executive made at an event run by The Atlantic last month. Moderna is also conducting a trial with children as young as six months old. References Fazel, M. et al. EClinicalMedicine 40, 101144 (2021) (The writer is a science journalist with a Bachelor's degree in Cognitive Neuroscience. This article was first published by Nature on 27 October 2021)  

Kapruka

Discover Kapruka, the leading online shopping platform in Sri Lanka, where you can conveniently send Gifts and Flowers to your loved ones for any event. Explore a wide range of popular Shopping Categories on Kapruka, including Toys, Groceries, Electronics, Birthday Cakes, Fruits, Chocolates, Automobile, Mother and Baby Products, Clothing, and Fashion. Additionally, Kapruka offers unique online services like Money Remittance, Astrology, Medicine Delivery, and access to over 700 Top Brands. Also If you’re interested in selling with Kapruka, Partner Central by Kapruka is the best solution to start with. Moreover, through Kapruka Global Shop, you can also enjoy the convenience of purchasing products from renowned platforms like Amazon and eBay and have them delivered to Sri Lanka.Send love straight to their heart this Valentine's with our thoughtful gifts!

Discover Kapruka, the leading online shopping platform in Sri Lanka, where you can conveniently send Gifts and Flowers to your loved ones for any event. Explore a wide range of popular Shopping Categories on Kapruka, including Toys, Groceries, Electronics, Birthday Cakes, Fruits, Chocolates, Automobile, Mother and Baby Products, Clothing, and Fashion. Additionally, Kapruka offers unique online services like Money Remittance, Astrology, Medicine Delivery, and access to over 700 Top Brands. Also If you’re interested in selling with Kapruka, Partner Central by Kapruka is the best solution to start with. Moreover, through Kapruka Global Shop, you can also enjoy the convenience of purchasing products from renowned platforms like Amazon and eBay and have them delivered to Sri Lanka.Send love straight to their heart this Valentine's with our thoughtful gifts!


More News..